{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=glecaprevir+%28300mg%29%2Fpibrentasvir+%28120mg%29",
    "query": {
      "intervention": "glecaprevir (300mg)/pibrentasvir (120mg)"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 4,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-10-09T22:03:47.281Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03117569",
      "title": "Trial of Simplified Treatment Monitoring for 8 Weeks Glecaprevir/Pibrentasvir in Chronic Hepatitis C Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hepatitis C, Chronic"
      ],
      "interventions": [
        {
          "name": "glecaprevir (300mg)/pibrentasvir (120mg)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Kirby Institute",
      "sponsor_class": "OTHER_GOV",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 380,
      "start_date": "2017-08-21",
      "completion_date": "2018-12-19",
      "has_results": true,
      "last_update_posted_date": "2019-12-11",
      "last_synced_at": "2026-10-09T22:03:47.281Z",
      "location_count": 4,
      "location_summary": "Boston, Massachusetts • New York, New York • Durham, North Carolina + 1 more",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        },
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03117569"
    },
    {
      "nct_id": "NCT04575896",
      "title": "Kidney Transplants in Hepatitis C Negative Recipients With Hepatitis C Viremic Donors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "End Stage Renal Disease",
        "Hepatitis C"
      ],
      "interventions": [
        {
          "name": "Glecaprevir/pibrentasvir",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Johns Hopkins University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 10,
      "start_date": "2020-11-20",
      "completion_date": "2023-12-01",
      "has_results": true,
      "last_update_posted_date": "2024-01-10",
      "last_synced_at": "2026-10-09T22:03:47.281Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04575896"
    },
    {
      "nct_id": "NCT03092375",
      "title": "Multi-Center, Randomized, Open-Label Study of G/P +/- RBV for NS5A + SOF Previously Treated GT1 HCV Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hepatitis C",
        "HCV"
      ],
      "interventions": [
        {
          "name": "Glecaprevir/Pibrentasvir (G/P) 300mg/120mg",
          "type": "DRUG"
        },
        {
          "name": "Ribavirin 200Mg Tablet",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Florida",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 177,
      "start_date": "2017-04-20",
      "completion_date": "2020-02-06",
      "has_results": true,
      "last_update_posted_date": "2020-02-26",
      "last_synced_at": "2026-10-09T22:03:47.281Z",
      "location_count": 31,
      "location_summary": "Palo Alto, California • San Francisco, California • Washington D.C., District of Columbia + 22 more",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03092375"
    },
    {
      "nct_id": "NCT03627299",
      "title": "Renal Transplants in Hepatitis C Negative Recipients With Nucleic Acid Positive Donors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "End Stage Renal Disease",
        "Hepatitis C"
      ],
      "interventions": [
        {
          "name": "300mg glecaprevir/pibrentasivir 120mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Johns Hopkins University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 11,
      "start_date": "2018-09-25",
      "completion_date": "2021-09-20",
      "has_results": true,
      "last_update_posted_date": "2021-10-19",
      "last_synced_at": "2026-10-09T22:03:47.281Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03627299"
    }
  ]
}